GlassScriptPhysician profile
Connie S Dimarco
NPI 1891712477
$2,638.85
in general payments reported to CMS, 2019-2025
10 companies · $56.74 in 2025
The $56.74 reported for 2025 was less than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.61 · 2020: $95.06 · 2022: $84.99 · 2023: $64.95 · 2024: $2,301 · 2025: $56.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,798 · Food and Beverage: $550 · Education: $64.95 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,798.28 |
| Food and Beverage | $550.22 |
| Education | $64.95 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,281.52 | 2024 | |
| Astellas Pharma US INC | $229.93 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $31.05 | 2025 | Lynparza |
| Abbvie INC. | $25.69 | 2025 | |
| Janssen Biotech, INC. | $22.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $15.07 | 2020 | |
| Endo Pharmaceuticals INC. | $14.29 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Dimarco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.